Related Experiment Video
Updated: May 8, 2026

Author Spotlight: Advancing Therapeutics to Treat Vibriosis in Humans and Aquatic Organisms
Published on: May 31, 2024
High-Throughput, High-Quality: Benchmarking GNINA and AutoDock Vina for Precision Virtual Screening Workflow
Rocco Buccheri1, Antonio Rescifina1
1Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.
Abstract:
Drug discovery is an intricate and resource-intensive process in which computational approaches, such as molecular docking, are essential, particularly in the early stages, to identify potential hits. However, docking still has many drawbacks, including problems in managing protein flexibility and the reliability of scoring functions. In this paper, we systematically compared the performance of AutoDock Vina, one of the most widely used open-source docking tools, with GNINA. This advanced evolution integrates convolutional neural networks (CNNs) for pose scoring. The comparison was conducted on ten heterogeneous protein targets, including metalloenzymes, kinases, and G-protein-coupled receptors (GPCRs). With the ability to accurately replicate binding poses and their energy values, GNINA showed outstanding performance in both virtual screening (VS) of active ligands and re-docking steps of co-crystallized ligands. GNINA's enhanced ability to accurately distinguish between true positives and false positives-a specificity not found with AutoDock Vina-is confirmed by ROC curves and Enrichment Factor (EF) results. Therefore, we propose an integrated GNINA-based workflow that can significantly enhance the quality and reliability of docking results, providing a valuable tool for optimizing the initial stages of drug discovery.
More Related Videos
08:49Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025